secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022305
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack reports Q3 net loss of $4.2M; cash $7.9M to fund through Q1 2026; IDE submission Spring 2026
--------------------------------------------------------------------------------

- Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.
- Cash and equivalents $7.9M at Sep 30, 2025; expected to fund operations through first quarter 2026.
- Secured $3M convertible note ($3.6M principal) and $20M ELOC; proceeds to repay note and eliminate warrant dilution.
- IDE submission for CBGM to FDA expected Spring 2026; long-term feasibility study initiated in Australia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315225022305/0001493152-25-022305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315225022305/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer